Regeneron's Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best innovative stocks to buy now. On September 17, Regeneron Pharmaceuticals announced updated analyses from the ongoing Phase 2 COURAGE trial for obesity. The complete 26-week results, which were presented as a late-breaking oral session at the 61st Annual Meeting of the European Association for the Study of Diabetes/EASD in September this year, investigate novel combinations of the GLP-1 receptor agonist semaglutide with trevogrumab (anti-GDF8/anti-myostatin), with or without garetosmab (anti-activin A).

The trial’s primary goal was to investigate the quality of weight loss in patients with obesity over a 26-week weight-loss phase, with an ensuing 26-week weight-maintenance phase. The results confirmed a key challenge of GLP-1 receptor agonists: 33% of the weight loss induced by semaglutide monotherapy was attributed to a loss of lean mass. However, all combination groups showed improved body composition with lean mass preservation and greater fat loss compared to semaglutide alone.

Across all treatment groups, including semaglutide monotherapy, numerical improvements were observed in secondary and exploratory metabolic and lipid parameters, such as waist circumference, blood pressure, cholesterol, triglycerides, and A1C. The combination of semaglutide with trevogrumab was generally well-tolerated. The safety and efficacy of trevogrumab and garetosmab have not been evaluated by any regulatory authority.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.